Pancreatic Cancer Market Outlook:
Pancreatic Cancer Market size was valued at USD 3.28 billion in 2025 and is likely to cross USD 12.05 billion by 2035, registering more than 13.9% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of pancreatic cancer is assessed at USD 3.69 billion.
The growth in the market is majorly attributed to the rising prevalence of associated malignancies across the world. According to a 2023 NLM article, the worldwide incidence of this carcinoma was 4.9 per 100,000, while having a mortality/incidence ratio of 94.0%. It also mentioned that the maximum annual new onsets were observed among people aged over 70 and between 50 and 69. On the other hand, WHO projected the global population of the age group of 60 and over to surpass 2.1 billion by 2050. Another estimation from the Journal of Gastrointestinal Oncology, released in July 2021, revealed that the number of new incidences of pancreatic cancer (PC) around the globe was 400,000 per year. This demographic represents a growing consumer base in this field.
Several studies have proven the importance of early detection to attain the best outcomes from the use of therapies available in the market. In support of this fact, in June 2021, a cost-effectiveness trial on risk-based PC screening in patients with new-onset diabetes (NOD) was published by the National Comprehensive Cancer Network. It presented a base case cost of USD 63,063.0 per quality-adjusted life years (QALY) gained, establishing this method of screen detection to be a cost-effective option for U.S. residents. Furthermore, dedicated companies are continuously investing in R&D to develop long-acting and safer therapeutics with affordable payers’ pricing to improve public access to advanced treatment.
